Market research
SPPI Spectrum Pharmaceuticals Inc
NASDAQ USD Healthcare
Latest close
As of 29 Dec 2024
Test a moving-average rule with historical data.
Market facts
- Market cap
- 211M
- P/E ratio
- Not available
- Analyst target
- 1.14
- Dividend yield
- 0.0%
- Beta
- 2.14
Profile
Instrument facts
- Exchange
- NASDAQ
- Currency
- USD
- Sector
- Healthcare
- Industry
- Biotechnology & Medical Research
- ISIN
- Not available
- Market cap
- 211M
- P/E ratio
- Not available
- Analyst target
- 1.14
- Dividend yield
- 0.0%
- Beta
- 2.14
About
About Spectrum Pharmaceuticals Inc
Spectrum Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes oncology drug products. It offers ROLVEDON(Eflapegrastim), a novel long-acting granulocyte colony-stimulating factor for chemotherapy-induced neutropenia. The company develops Poziotinib, a novel irreversible tyrosine kinase inhibitor for non-small cell lung cancer tumors with various mutations. It has co-development, commercialization, and in-license agreements with Hanmi Pharmaceutical Co. Ltd.; a patent and technology license agreement with The University of Texas M.D. Anderson Cancer Center; and license agreement with Therapyx, Inc. The company was formerly known as NeoTherapeutics, Inc. and changed its name to Spectrum Pharmaceuticals, Inc. in December 2002. Spectrum Pharmaceuticals, Inc. was incorporated in 1987 and is headquartered in Boston, Massachusetts. As of July 31, 2023, Spectrum Pharmaceuticals, Inc. operates as a subsidiary of Assertio Holdings, Inc.
Research context
Spectrum Pharmaceuticals Inc appears in PyInvesting’s US Stock catalogue. The price history above describes this recorded instrument; it does not by itself identify a company’s business or establish a continuous investment return.
- Currency
- USD
- Sector
- Healthcare
- Industry
- Biotechnology & Medical Research
These are the latest stored catalogue classifications, not a historical classification snapshot. An issuer description, classification effective date or currency may be unavailable. Check the issuer’s own disclosures and the observation dates before using these fields for research.
Review backtest assumptions and evidence before treating a chart or stored history as a research result.
Community
Investor discussion
1 comment
Sign in to join the SPPI discussion.
5 years, 6 months ago
Spectrum Pharmaceuticals, Inc is currently in a long term downtrend where the price is trading 4.7% below its 200 day moving average.
From a valuation standpoint, the stock is 100.0% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 0.0.
Spectrum Pharmaceuticals, Inc's total revenue sank by nan% to $0 since the same quarter in the previous year.
Its net income has dropped by 1.5% to $-40M since the same quarter in the previous year.
Finally, its free cash flow fell by 10.2% to $-35M since the same quarter in the previous year.
Based on the above factors, Spectrum Pharmaceuticals, Inc gets an overall score of 1/5.